Radiation therapy plus an immunotherapy drug for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination for liver cancer that has not responded to one earlier treatment. It uses a focused type of radiation (SBRT) plus an immunotherapy drug called QL1706 (a medicine that helps your immune system attack cancer). The goal is to see if this combination can control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have liver cancer that has not spread outside the liver, and you have no more than 3 tumors in the liver.
- You have tried one previous treatment (like sorafenib or lenvatinib) and it stopped working or caused bad side effects.
- Your liver is still working fairly well (Child-Pugh A or B score 7).
- You have not had a specific type of radiation called Y-90 before.
- You are willing to receive both radiation therapy and an immunotherapy drug (QL1706).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.